
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3696472/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6212-6222.	3.2	1,012
2	STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Molecular Cancer, 2017, 16, 136.	7.9	434
3	Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncology, The, 2012, 13, 817-826.	5.1	337
4	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57, 1458-1468.	3.6	331
5	Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 146.	7.1	320
6	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59, 953-962.	6.1	238
7	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1151-1173.	1.2	160
8	Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1155-1163.	1.2	154
9	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110Î ² and predicts poor prognosis. Journal of Hematology and Oncology, 2019, 12, 37.	6.9	150
10	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. Clinical Cancer Research, 2008, 14, 3850-3859.	3.2	143
11	A Positive Feedback Loop Between Cancer Stemâ€Like Cells and Tumorâ€Associated Neutrophils Controls Hepatocellular Carcinoma Progression. Hepatology, 2019, 70, 1214-1230.	3.6	140
12	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. Clinical Cancer Research, 2009, 15, 5518-5527.	3.2	122
13	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 547-559.	3.2	112
14	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis, 2013, 34, 2071-2079.	1.3	109
15	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 2203-2213.	3.2	102
16	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform. Clinical Cancer Research, 2014, 20, 4794-4805.	3.2	99
17	A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. Cancer Letters, 2019, 450, 98-109.	3.2	94
18	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nature Communications, 2021, 12, 4091.	5.8	90

#	Article	IF	CITATIONS
19	Up-regulation of Krüppel-Like Factor 8 Promotes Tumor Invasion and Indicates Poor Prognosis for Hepatocellular Carcinoma. Gastroenterology, 2010, 139, 2146-2157.e12.	0.6	88
20	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 293-301.	1.8	79
21	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. BMC Cancer, 2019, 19, 760.	1.1	78
22	Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology, 2013, 57, 1088-1097.	3.6	74
23	High expression of Dickkopfâ€related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer, 2013, 119, 993-1003.	2.0	73
24	Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection. Oncologist, 2008, 13, 1155-1165.	1.9	69
25	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death and Disease, 2020, 11, 573.	2.7	65
26	Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1963-1969.	1.4	61
27	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2015, 468, 525-532.	1.0	59
28	Circulating CD14 ⁺ HLAâ€DR ^{â^'/low} myeloidâ€derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatology Research, 2017, 47, 1061-1071.	1.8	56
29	Overexpression of galectinâ€1 is associated with poor prognosis in human hepatocellular carcinoma following resection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1312-1319.	1.4	52
30	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5â€LSD1â€NFâ€ÎºB oncogenic signaling. Clinical and Translational Medicine, 2020, 10, e233.	1.7	51
31	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. Journal of Hepatology, 2019, 71, 1152-1163.	1.8	49
32	Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clinica Chimica Acta, 2016, 462, 15-22.	0.5	47
33	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget, 2016, 7, 70654-70668.	0.8	44
34	Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma. PLoS ONE, 2013, 8, e54619.	1.1	43
35	Establishment of a hepatocellular carcinoma patientâ€derived xenograft platform and its application in biomarker identification. International Journal of Cancer, 2020, 146, 1606-1617.	2.3	32
36	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver International, 2021, 41, 562-573.	1.9	32

#	Article	IF	CITATIONS
37	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death and Disease, 2018, 9, 1036.	2.7	31
38	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 47121-47135.	0.8	29
39	Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2016, 47, 157-167.	0.6	27
40	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. Journal of Cancer, 2019, 10, 3914-3925.	1.2	27
41	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NFâ€kB signaling pathways synergistically. Clinical and Translational Medicine, 2021, 11, e335.	1.7	27
42	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2018, 25, 1686-1694.	0.7	25
43	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A singleâ€center, retrospective, propensityâ€matched study. Clinical and Translational Medicine, 2020, 10, e137.	1.7	25
44	An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. Molecular Therapy, 2022, 30, 2554-2567.	3.7	24
45	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine, 2020, 62, 103107.	2.7	23
46	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. Cancer Letters, 2015, 366, 112-122.	3.2	21
47	PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer, 2018, 18, 550.	1.1	20
48	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathology, 2020, 128, 733-745.	1.4	19
49	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity scoreâ€matched survival analysis. Cancer Medicine, 2019, 8, 6933-6944.	1.3	14
50	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. Hepatic Oncology, 2015, 2, 231-244.	4.2	13
51	Significance of PIVKA‑II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus‑associated hepatocellular carcinoma. Oncology Letters, 2018, 15, 8396-8404.	0.8	13
52	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clinical and Translational Medicine, 2022, 12, e794.	1.7	13
53	A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. Lipids in Health and Disease, 2017, 16, 123.	1.2	11
54	Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. Journal of Cancer, 2017, 8, 1338-1346.	1.2	11

#	Article	IF	CITATIONS
55	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death and Disease, 2020, 11, 895.	2.7	11
56	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 2022, 36, e24259.	0.9	10
57	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist, 2019, 24, 997-1007.	1.9	9
58	Circulating tumor cell detection and single ell analysis using an integrated workflow based on ChimeraX [®] â€i120 Platform: A prospective study. Molecular Oncology, 2021, 15, 2345-2362.	2.1	9
59	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clinica Chimica Acta, 2020, 511, 67-74.	0.5	8
60	Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma. Journal of Cancer, 2021, 12, 6937-6947.	1.2	8
61	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. Signal Transduction and Targeted Therapy, 2022, 7, 24.	7.1	7
62	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. OncoTargets and Therapy, 2016, Volume 9, 6281-6290.	1.0	5
63	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Frontiers in Oncology, 2021, 11, 704042.	1.3	5
64	Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. Journal of Cancer, 2021, 12, 7190-7200.	1.2	5
65	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 2465-2477.	1.4	5
66	Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miRâ€34câ€5p/LGR4/βâ€catenin axis activity. Journal of Cellular and Molecular Medicine, 2022, , .	1.6	4
67	Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 112-120.	0.6	2
68	ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2019, 26, 529-530.	0.7	1
69	Dickkopf-1 and hepatocellular carcinoma – Authors' reply. Lancet Oncology, The, 2012, 13, e410-e411.	5.1	0